Progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|1|7-10

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.1, 2014-01, pp. : 7-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reply to progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By  

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1907

John Wiley & Sons Inc

Access to resources Recommend Favorite

Progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By  

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1906

John Wiley & Sons Inc

Access to resources Recommend Favorite

Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

By  

CANCER, Vol. 120, Iss. 1, 2014-01 ,pp. : 52-60

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials

By  

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1737-1746

John Wiley & Sons Inc

Access to resources Recommend Favorite

Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial Data

By  

Oncology Research and Treatment, Vol. 38, Iss. 3, 2015-02 ,pp. : 88-94

Karger

Access to resources Recommend Favorite